ArticleAddiction (Abingdon, England)2025
Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada.
Article in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methodological innovations to advance substance use disorder research: Proceedings of a NIDA workshop on target trial emulation and translational testing of digital health tools.Journal of substance use and addiction treatment · 2026Article
- Factors influencing family physicians' willingness to prescribe opioid agonist therapy using virtual modalities: a qualitative analysis.Frontiers in medicine · 2026Article
- Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada.Addiction (Abingdon, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
aimUrine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self-reported substance use, monitoring for diversion and supporting clinical decisions for take-home dosing. However, there is a paucity of evidence to support the practice of urine drug testing. We aimed to determine the association of alternative urine drug testing frequencies with opioid agonist treatment discontinuation, compared with no monitoring, among individuals receiving methadone or buprenorphine/naloxone treatment.
designPopulation-based retrospective cohort study and target trial emulation based on nine-linked administrative databases.
settingBritish Columbia, Canada, between 1 January 2010 and 17 March 2020.
participantsIndividuals with no history of cancer or palliative care, aged 18 or older and no indication of pregnancy who initiated methadone or buprenorphine/naloxone. A total of 18 988 methadone and 11 910 buprenorphine/naloxone recipients were included in the incident user design (individuals with no past opioid agonist treatment experience). MEASUREMENTS: We used a clone-censor-weight approach to estimate hazard ratios with 95% compatibility ("confidence") intervals for treatment discontinuation (lasting at least 5 and 6 days for methadone and buprenorphine, respectively) and all-cause mortality on treatment within 12 months for static urine drug testing strategies.
findingsUnder static monitoring strategies, weekly urine drug testing was associated with a slightly reduced risk of discontinuation in the first year of continuous retention in treatment [methadone: adjusted hazard ratio (aHR) = 0.96, 95% compatibility interval (CI) = (0.95-0.98); buprenorphine/naloxone: aHR = 0.95 (0.94-0.97)] compared with no monitoring. The estimated associations of weekly urine drug testing with all-cause mortality were similar in size but extremely imprecise [methadone: aHR = 0.95 (0.78-1.15), buprenorphine/naloxone: aHR = 0.99 (0.62-1.58)]. Less frequent testing demonstrated no observed difference on treatment discontinuation or all-cause mortality compared with no monitoring.
conclusionCompared with no urine drug testing, weekly urine drug testing may be associated with improved opioid agonist treatment retention; however, the high costs attributable to frequent testing may not be cost-effective and requires further evaluation. There was no improvement associated with less frequent testing compared with no monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.